

Company Overview

Baudax Bio is a specialty pharmaceutical company focused on developing and commercializing innovative products for patients in acute care settings. Baudax Bio was spun-out from Recro Pharma, Inc (REPH) in 2019 when Recro Pharma, Inc. separated its Acute Care Division from its Contract Drug Manufacturing Organization that together were "Recro Pharma". We are committed to bringing clinically meaningful therapeutic options to patients, health care providers, and payers, such as our lead product candidate, injectable meloxicam. We believe we can create value for patients and shareholders through our robust pipeline of product candidates. In addition, we continue to evaluate acquisition and licensing opportunities which align with our core acute care focus.

Our lead product candidate is a proprietary IV injectable form of meloxicam, a long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed three Phase III clinical trials, including two pivotal efficacy trials, a large double-blind Phase III safety trial and other safety studies for the management of moderate to severe pain. Overall, the total New Drug Application (NDA) program included over 1,400 patients. We received two Complete Response Letters (CRL) for IV Meloxicam which we appealed to the first level and our appeal was granted. We are preparing a refiling of the NDA with a comprehensive response to the letter. Revised prescribing information will be included, along with the required update to safety summaries since the last filing.

We believe that IV meloxicam compares favorably to competitive non-opioid therapies in onset of pain relief, duration of pain relief, extent of pain relief in addition to being well tolerated by patients in clinical trials. IV meloxicam, as a non-opioid product, could overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, excessive nausea and vomiting, constipation, as well having no addiction potential. We believe it can be an important part of a multimodal analgesia (MMA) approach for patients in surgical pain settings.

Our pipeline also includes other early-stage product candidates, including two novel neuromuscular blocker agents (NMBs) and a related proprietary chemical reversal agent, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine, a selective alpha-2 adrenergic agonist that has demonstrated sedative, analgesic and anxiolytic properties.

[Baudax Bio Announces Closing of \\$25 Million Public Offering of Securities](#)

Mar 26 2020, 11:35 AM EDT

[Baudax Bio Announces Pricing of Public Offering of Common Stock and Warrants](#)

Mar 24 2020, 9:15 AM EDT

[Baudax Bio Announces Proposed Public Offering of Common Stock and Warrants](#)

Mar 23 2020, 4:20 PM EDT

Management Team

Gerri Henwood

President & Chief Executive Officer

Ryan D. Lake

Chief Financial Officer

Stewart McCallum, MD

Chief Medical Officer

John Harlow

Chief Commercial Officer

Randy Mack

Senior Vice President, Development

Diane Myers

Senior Vice President, Regulatory & Quality

Jyrki Mattila, M.D., Ph.D.

Executive Vice President of Business Development

Baudax Bio, Inc.

490 Lapp Road
Malvern, PA 19355

Stock Overview

Symbol BXR
Exchange Nasdaq
Market Cap 25m
Last Price \$2.65
52-Week Range \$2.16 - \$10.14

Investor Relations

Argot Partners
Sam Martin
sam@argotpartners.com

03/27/2020 04:00 PM EDT

Disclaimer

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.